SBFM ▼ -2.6% - Sunshine Biopharma, Inc. $SBFM - Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions Sunshine Biopharma's stock declined 2.6% despite receiving Health Canada approval for its atenolol treatment for cardiovascular conditions. The regulatory clearance represents a significant milestone for the company's product pipeline and would typically be expected to support the stock price. The disconnect between the positive news and the intraday decline suggests other market factors may be weighing on investor sentiment today. 31-AUG-2026 09:00 AM ET